Breaking News Instant updates and real-time market news.

RDFN

Redfin

$27.56

0.86 (3.22%)

, EGN

Energen

$50.21

0.65 (1.31%)

10:29
08/22/17
08/22
10:29
08/22/17
10:29

On The Fly: Top five analyst initiations

Catch up on the today's top five analyst initiations with this list compiled by The Fly: 1. Redfin (RDFN) initiated with a Sector Perform at RBC Capital, Hold rating at Stifel, an Outperform at Oppenheimer and Neutral at Goldman Sachs. 2. Energen (EGN) initiated with an Outperform at Imperial Capital. 3. Pioneer Natural (PXD) initiated with an Outperform at Imperial Capital. 4. Revance (RVNC) initiated with an Outperform at JMP Securities. 5. Pacira (PCRX) initiated with a Buy at Needham. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

RDFN

Redfin

$27.56

0.86 (3.22%)

EGN

Energen

$50.21

0.65 (1.31%)

PXD

Pioneer Natural

$128.63

0.69 (0.54%)

RVNC

Revance

$22.70

-0.45 (-1.94%)

PCRX

Pacira

$35.75

-0.05 (-0.14%)

  • 29

    Aug

  • 06

    Sep

  • 25

    Sep

  • 02

    Nov

RDFN Redfin
$27.56

0.86 (3.22%)

08/22/17
RBCM
08/22/17
INITIATION
RBCM
Sector Perform
Redfin initiated with a Sector Perform at RBC Capital
RBC Capital analyst Mark Mahaney started coverage of Redfin with a $28 price target and a Sector Perform rating. He says that the company has strong fundamentals and "should...create shareholder value" over the "long-term." However, he says the stock is currently "reasonably valued." Target $28. .
08/22/17
STFL
08/22/17
INITIATION
STFL
Hold
Redfin initiated with a Hold at Stifel
Stifel analyst John Egbert started coverage of Redfin with a $24 price target and a Hold rating. The analyst says that the company's model of paying its agents a salary and charging "below-market commissions" is "disruptive," but he thinks that the stock is currently fairly valued. However, he is upbeat on the company's longer term outlook.
08/22/17
OPCO
08/22/17
INITIATION
Target $31
OPCO
Outperform
Redfin initiated with an Outperform at Oppenheimer
Oppenheimer analyst Jason Helfstein started Redfin with an Outperform rating and $31 price target.
08/22/17
BOFA
08/22/17
INITIATION
Target $28
BOFA
Neutral
Redfin initiated with a Neutral at BofA/Merrill
BofA/Merrill initiated Redfin with a Neutral and a $28 price target.
EGN Energen
$50.21

0.65 (1.31%)

08/22/17
IMPC
08/22/17
INITIATION
Target $61
IMPC
Outperform
Energen initiated with an Outperform at Imperial Capital
Imperial Capital analyst Irene Haas initiated Energen with an Outperform and a $61 price target. Energen has divested its non-Permian and non E&P assets during the downturn and has built up a sizeable inventory in the Delaware Basin and Midland, the analyst wrote in a report. Haas said Energen now has a robust growth profile, and has demonstrated it is a good operator.
08/11/17
GHSC
08/11/17
UPGRADE
Target $46
GHSC
Neutral
Energen Energen upgraded to Neutral from Sell at Seaport Global
Seaport Global analyst Mike Kelly upgraded Energen to Neutral and increased its price target to $46 from $38 citing inreased confidence in execution and asset quality. The analyst said Energen had impressive results from both its Gen 3 completions and from its pattern/batch completions in the Midland and Delaware basins.
07/20/17
JPMS
07/20/17
DOWNGRADE
Target $53
JPMS
Neutral
Energen downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Michael Glick downgraded Energen (EGN) to Neutral saying he's repositioning his ratings ahead of the Q2 reporting season toward names that can perform well in a lower commodity price environment. The analyst calls Parsley Energy (PE) and Diamondback Energy (FANG) his top picks in the small-to-mid cap Exploration & Production space. He lowered his price target for Energen shares to $53 from $60.
06/21/17
GHSC
06/21/17
DOWNGRADE
Target $38
GHSC
Sell
Energen downgraded to Sell from Neutral at Seaport Global
Seaport Global analyst Mike Kelly downgraded Energen to Sell and slashed its price target to $38 from $61 to reflect a new commodity price deck. Seaport Global's Energy team reduced its long-term oil forecast to $40/bbl from $50/bbl to reflect "relentless" US production growth. The firm sees the potential for the oil market to be "significantly over supplied in 2018 and cut its oil price forecast for first half 2017 to $45/bbl from $55/bbl and first half 2018 to $35/bbl from $55/bbl.
PXD Pioneer Natural
$128.63

0.69 (0.54%)

08/09/17
GSCO
08/09/17
NO CHANGE
GSCO
Buy
Pioneer Natural share pullback overdone, says Goldman Sachs
Goldman analyst Brian Singer said the recent sharp pullback in Pioneer Natural shares is overdone. The analyst said lowered 2017 oil mix guidance is being incorrectly interpreted by the Street as a negative for Permian economics. Singer does not believe there has been any underperformance of oil production to more gas and the same oil and reiterates his Buy rating.
08/08/17
DBAB
08/08/17
NO CHANGE
DBAB
Deutsche views Pioneer Natural, peers as 'significantly oversold'
Deutsche Bank analyst Ryan Todd believes Pioneer Natural Resources (PXD) as well as the Permian Exploration & Production space are "significantly oversold" following Pioneer's Q2 results last week. The higher gas content of the production stream started an investor debate around the long-term risks to Permian production and resource value, Todd tells investors in a research note. He calls investor fears "wildly overblown" and is a buyer of the group, especially Pioneer Natural. The analyst has Buy ratings on the shares as well as Anadarko Petroleum (APC), ConocoPhillips (COP), Chevron (CVX) and Devon Energy (DVN).
08/22/17
IMPC
08/22/17
INITIATION
Target $160
IMPC
Outperform
Pioneer Natural initiated with an Outperform at Imperial Capital
Imperial Capital analyst Irene Haas initiated Pioneer Natural with an Outperform and a $160 price target saying it is a first mover and leader in the Midland Basin. Recent drilling issues are being remediated and concerns of much gassier Midland Basin are overdone, the analyst wrote. Haas views Pioneer as a high growth, low net debt opportunity.
08/08/17
STFL
08/08/17
NO CHANGE
STFL
Pioneer Natural shares oversold, says Stifel
Stifel analyst Derrick Whitfield says that Pioneer is "oversold" on both fundamentals and technicals. He says the company has "a modest execution overhang" following its Q2 results, but he thinks the stock has priced in the worst case scenario for dealing with salt water disposal over the long-term. The analyst believes that the company has addressed its execution issues while the stock is 20% undervalued. He keeps a $236 price target and a Buy rating on the shares.
RVNC Revance
$22.70

-0.45 (-1.94%)

11/29/16
AGIS
11/29/16
INITIATION
Target $28
AGIS
Buy
Revance initiated with a Buy at Aegis
Aegis analyst Difei Yang initiated Revance with a Buy and a $28 price target.
05/19/17
RHCO
05/19/17
NO CHANGE
RHCO
Revance data positive, says SunTrust
After Revance reported data on its RT002 for Cervical Dystonia, SunTrust analyst John Boris says that the greater than 24 week duration for the drug versus 8-12 week for competing drugs is "impressive." The analyst recommends buying the stock ahead of upcoming data.
08/22/17
JMPS
08/22/17
INITIATION
JMPS
Outperform
Revance initiated with an Outperform at JMP Securities
JMP Securities analyst Donald Ellis started coverage of Revance with a $34 price target and an Outperform rating. He says that the efficacy of the company's RT002 injectable botulinum toxin appears to last six months, versus three months for competing treatments. The analyst thinks that Revance's treatment "will have cost and quality-of-life benefits for patients," and he expects the stock to rise going forward.
07/21/17
CANT
07/21/17
INITIATION
Target $50
CANT
Overweight
Revance initiated with an Overweight at Cantor
Cantor Fitzgerald analyst Louise Chen started Revance Therapeutics with an Overweight rating and $50 price target. The analyst sees positive news flow for the company's key programs in development driving both estimates and the shares higher. Chen expect Revance to report positive results before the end of the year for its Phase 3 pivotal trials for glabellar lines and Phase 2 results for its new indication, plantar fasciitis.
PCRX Pacira
$35.75

-0.05 (-0.14%)

08/21/17
08/21/17
UPGRADE
Target $36

Neutral
Pacira upgraded to Neutral after pullback at Janney Capital
As previously reported, Janney Capital analyst Ken Trbovich upgraded Pacira to Neutral from Sell, saying he no longer sees significant downside after the stock's nearly 30% decline over the past month. However, he believes upside is dependent on growth for Exparel accelerating to at least the upper-end of the company's guidance of 12%-27% in the second half. He keeps a $36 fair value estimate on Pacira shares.
07/27/17
JANY
07/27/17
NO CHANGE
Target $36
JANY
Sell
Pacira overvalued even after mixed nerve block data selloff, says Janney Capital
Janney Capital analyst Ken Trbovich noted that Pacira shares sold off 15% after the company reported mixed Phase 3 data from its nerve block studies, but he believes the stock is still overvalued. While he still believes the label expanding sNDA will be approved 6 months after the sNDA is filed, he does not believe the filing can happen until Q4 of this year, leading him to push back his projections of Exparel Rx growth until Q2 of 2018. Trbovich maintains a Sell rating and $36 fair value estimate on Pacira shares.
08/22/17
NEED
08/22/17
INITIATION
NEED
Buy
Pacira initiated with a Buy at Needham
Needham analyst Serge Belanger started coverage of Pacira with a $55 price target and a Buy rating. He says that data indicate that the company's non-opioid pain treatment has a :"compelling" growth outlook. The analyst thinks that the company's sales will rise as soon as 2H17, and he believes that the decline in the stock has created an attractive entry point.
08/21/17
JANY
08/21/17
UPGRADE
JANY
Neutral
Pacira upgraded to Neutral from Sell at Janney Capital

TODAY'S FREE FLY STORIES

GNRT

Gener8 Maritime

, EURN

Euronav NV

05:13
01/23/18
01/23
05:13
01/23/18
05:13
Downgrade
Gener8 Maritime, Euronav NV rating change  »

Gener8 Maritime…

GNRT

Gener8 Maritime

EURN

Euronav NV

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUS

Nu Skin

$70.84

0.85 (1.21%)

05:11
01/23/18
01/23
05:11
01/23/18
05:11
Recommendations
Nu Skin analyst commentary  »

Nu Skin price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

NFLX

Netflix

$227.58

7.12 (3.23%)

05:08
01/23/18
01/23
05:08
01/23/18
05:08
Recommendations
Netflix analyst commentary  »

Netflix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

NTR

Nutrien

$53.07

0.07 (0.13%)

05:05
01/23/18
01/23
05:05
01/23/18
05:05
Upgrade
Nutrien rating change  »

Nutrien upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 06

    Feb

NFLX

Netflix

$227.58

7.12 (3.23%)

05:01
01/23/18
01/23
05:01
01/23/18
05:01
Recommendations
Netflix analyst commentary  »

Netflix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

ADBE

Adobe

$197.84

2.11 (1.08%)

05:00
01/23/18
01/23
05:00
01/23/18
05:00
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

ATUS

Altice USA

$21.90

0.6 (2.82%)

, ALLVF

Altice NV

$11.35

0.3675 (3.35%)

04:58
01/23/18
01/23
04:58
01/23/18
04:58
Upgrade
Altice USA, Altice NV rating change  »

Altice USA upgraded to…

ATUS

Altice USA

$21.90

0.6 (2.82%)

ALLVF

Altice NV

$11.35

0.3675 (3.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$227.58

7.12 (3.23%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Recommendations
Netflix analyst commentary  »

Netflix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

ALLVF

Altice NV

$11.35

0.3675 (3.35%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Upgrade
Altice NV rating change  »

Altice NV upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Wolfe Research utilities analyst to hold a luncheon meeting »

Senior Utilities Analyst…

RHT

Red Hat

$128.01

2.07 (1.64%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Red Hat participates in a conference call with Bernstein »

U.S. SMID-Cap Software…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 06

    Feb

CAMP

CalAmp

$23.13

0.02 (0.09%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
CalAmp has a conference call hosted by JPMorgan »

JPMorgan Analyst Coster…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

AYR

Aircastle

$24.23

-0.03 (-0.12%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Aircastle management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

CRNCY

Cairn Energy

$6.15

0.11 (1.82%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Cairn Energy management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

SRE

Sempra Energy

$105.05

-0.94 (-0.89%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Sempra Energy management to meet with Wolfe Research »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

TRN

Trinity Industries

$36.51

-0.15 (-0.41%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Trinity Industries management to meet with Wedbush »

Meeting with CFO Perry…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

EPE

EP Energy

$2.48

0.17 (7.36%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
EP Energy to hold a conference call »

Management discusses its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

SBOW

SilverBow Resources

$31.45

-0.79 (-2.45%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
SilverBow Resources management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

BNED

Barnes & Noble Education

$7.71

0.01 (0.13%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Barnes & Noble Education management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

BRG

Bluerock Residential

$9.22

0.03 (0.33%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Bluerock Residential management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

FCPT

Four Corners Property Trust

$24.13

0.45 (1.90%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Four Corners Property Trust management to meet with JMP Securities »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

SIG

Signet Jewelers

$55.87

0.8 (1.45%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Signet Jewelers management to meet with Buckingham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

UNF

UniFirst

$171.15

0.2 (0.12%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
UniFirst management to meet with Northcoast »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

PRQR

ProQR Therapeutics

$3.03

0.025 (0.83%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
ProQR Therapeutics to h old an investor event »

Investor Event will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 19

    Feb

CQH

Cheniere Energy Partners LP

$28.50

0.28 (0.99%)

, CQP

Cheniere Energy Partners

$30.89

0.41 (1.35%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Morgan Stanley to hold a tour »

Annual Morgan Stanley…

CQH

Cheniere Energy Partners LP

$28.50

0.28 (0.99%)

CQP

Cheniere Energy Partners

$30.89

0.41 (1.35%)

ENLC

EnLink Midstream

$19.25

0.5 (2.67%)

ENLK

EnLink Midstream Partners

$18.08

0.63 (3.61%)

EPD

Enterprise Products

$29.40

0.74 (2.58%)

NBLX

Noble Midstream

$56.22

1.12 (2.03%)

PAA

Plains All American

$23.05

0.56 (2.49%)

SHLX

Shell Midstream

$30.46

0.33 (1.10%)

TRGP

Targa Resources

$51.00

0.27 (0.53%)

WES

Western Gas Partners

$53.74

1.43 (2.73%)

WGP

Western Gas Equity

$41.91

1.49 (3.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 16

    Feb

  • 20

    Feb

  • 26

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.